Earlier MD Anderson investigations demonstrated exosomes as a factor in detecting pancreatic cancer, but these latest findings reveal genetically altered exosomes as a potentially novel approach for direct and specific targeting of mutated KRAS, the cancer gene commonly linked to pancreatic cancer.
In the study, exosomes, which are generated by all cells and are naturally present in blood, were modified as “iExosomes,” capable of delivering small RNA to specifically target mutant KRAS, resulting in disease suppression and increased overall survival in mouse models. The investigators utilized a targeting method called RNA interference (RNAi) which, when delivered via these natural nanoparticles or exosomes, zero in on mutant KRAS in pancreas cancer cells, impacting tumor burden and survival in multiple pancreas cancer models. The team showed that exosomes could serve as an efficient carrier of RNAi, given that these nano-sized vesicles easily travel across the body and enter cells, including cancer cells.
When mutated, KRAS acts as a molecular on-off switch that gets stuck in an “on” position. It is mutated in 80 to 95 percent of pancreatic ductal adenocarcinomas (PDAC), the most frequent mutation in this cancer. The study demonstrated that iExosomes were able to deliver KRAS-specific targeting genetic material called siRNA and shRNA, and were more efficient than their synthetic counterpart, iLiposomes, which do not present with the natural complexities and advantages that exosomes display.
“Our studies suggest that exosomes exhibit a superior ability to deliver siRNA molecules and suppress aggressive pancreatic tumor growth when compared to liposomes,” said LeBleu. “We also demonstrated that the presence of CD47 on exosomes allows for evasion from phagocytosis by the circulating monocytes.”
CD47 is a protein involved in many cellular processes, including cell death, growth and migration. Phagocytosis is a process by which white blood cells called macrophages digest cellular debris and foreign bodies and particles. Monocytes are the largest kind of white blood cell important to the immune system.
Until this study, a direct and specific targeting of KRAS has been elusive.
Read more about this study in MD Anderson’s Newsroom.